FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281645352> ?p ?o ?g. }

• W4281645352 endingPage "816" @default.
• W4281645352 startingPage "808" @default.
• W4281645352 abstract "Objective The objective of this study was to assess the face validity of a disease model evaluating the cost-effectiveness of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).Methods This was a Delphi panel study comprising of physicians with first-hand experience of ataluren for the treatment of nmDMD. Consensus was sought for previously unvalidated model data, including patient health status and quality of life measured using the Health Utility Index (HUI), mortality, informal caregiving, and the expected benefit of early ataluren treatment across four states: (1) ambulatory, (2) non-ambulatory, not yet requiring ventilation support, (3) non-ambulatory, night-time ventilation support, and (4) non-ambulatory, full-time ventilation support.Results Nine experts from five countries participated in the Delphi panel. Consensus was obtained for all questions after three panel rounds (except for two HUI-questions concerning hand function [dexterity]). Consensus HUI-derived utilities for state (1) were 1.0000 for ataluren on top of best supportive care (BSC) and 0.7337 for BSC alone. Corresponding estimates for state (2) were 0.3179 and 0.2672, for state (3) 0.1643 and 0.0913, and for state (4) −0.0732 and −0.1163. Consensus mortality rates for states (1), (2), and (3) were 4%, 13%, and 33%, and life expectancy in state (4) was agreed to be 3 years. Panelists further agreed that two informal caregivers typically provide day-to-day care/support to patients with nmDMD, and that starting treatment with ataluren at 2 versus 5 years of age would be expected to delay loss of ambulation by an additional 2 years, and initiation of night-time and full-time ventilation support by an additional 3 years, respectively.Limitations The main limitation concerns the size of the Delphi panel, govern primarily by the rarity of the disease.Conclusion This study confirms the face validity of key clinical parameters and assumptions underlying the ataluren cost-effectiveness model." @default.
• W4281645352 created "2022-06-13" @default.
• W4281645352 creator A5008900498 @default.
• W4281645352 creator A5010638215 @default.
• W4281645352 creator A5013168625 @default.
• W4281645352 creator A5044225676 @default.
• W4281645352 creator A5045978747 @default.
• W4281645352 creator A5050091481 @default.
• W4281645352 creator A5053209536 @default.
• W4281645352 creator A5066191468 @default.
• W4281645352 creator A5078176065 @default.
• W4281645352 creator A5084624493 @default.
• W4281645352 creator A5087859341 @default.
• W4281645352 creator A5091435937 @default.
• W4281645352 date "2022-06-14" @default.
• W4281645352 modified "2023-10-18" @default.
• W4281645352 title "Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study" @default.
• W4281645352 cites W1508659364 @default.
• W4281645352 cites W2001407064 @default.
• W4281645352 cites W2035041709 @default.
• W4281645352 cites W2037809152 @default.
• W4281645352 cites W2039906750 @default.
• W4281645352 cites W2080417224 @default.
• W4281645352 cites W2116638944 @default.
• W4281645352 cites W2120361462 @default.
• W4281645352 cites W2141952788 @default.
• W4281645352 cites W2154041187 @default.
• W4281645352 cites W2170268560 @default.
• W4281645352 cites W2194206520 @default.
• W4281645352 cites W2314780373 @default.
• W4281645352 cites W2608444169 @default.
• W4281645352 cites W2735778907 @default.
• W4281645352 cites W2770733887 @default.
• W4281645352 cites W2808048689 @default.
• W4281645352 cites W2996772860 @default.
• W4281645352 cites W3007566055 @default.
• W4281645352 cites W3043314395 @default.
• W4281645352 cites W3130661172 @default.
• W4281645352 cites W3136276473 @default.
• W4281645352 cites W3193467589 @default.
• W4281645352 cites W4223988478 @default.
• W4281645352 doi "https://doi.org/10.1080/13696998.2022.2085444" @default.
• W4281645352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35642753" @default.
• W4281645352 hasPublicationYear "2022" @default.
• W4281645352 type Work @default.
• W4281645352 citedByCount "1" @default.
• W4281645352 countsByYear W42816453522023 @default.
• W4281645352 crossrefType "journal-article" @default.
• W4281645352 hasAuthorship W4281645352A5008900498 @default.
• W4281645352 hasAuthorship W4281645352A5010638215 @default.
• W4281645352 hasAuthorship W4281645352A5013168625 @default.
• W4281645352 hasAuthorship W4281645352A5044225676 @default.
• W4281645352 hasAuthorship W4281645352A5045978747 @default.
• W4281645352 hasAuthorship W4281645352A5050091481 @default.
• W4281645352 hasAuthorship W4281645352A5053209536 @default.
• W4281645352 hasAuthorship W4281645352A5066191468 @default.
• W4281645352 hasAuthorship W4281645352A5078176065 @default.
• W4281645352 hasAuthorship W4281645352A5084624493 @default.
• W4281645352 hasAuthorship W4281645352A5087859341 @default.
• W4281645352 hasAuthorship W4281645352A5091435937 @default.
• W4281645352 hasBestOaLocation W42816453521 @default.
• W4281645352 hasConcept C124306116 @default.
• W4281645352 hasConcept C126322002 @default.
• W4281645352 hasConcept C133925201 @default.
• W4281645352 hasConcept C160735492 @default.
• W4281645352 hasConcept C162324750 @default.
• W4281645352 hasConcept C171606756 @default.
• W4281645352 hasConcept C1862650 @default.
• W4281645352 hasConcept C187212893 @default.
• W4281645352 hasConcept C194828623 @default.
• W4281645352 hasConcept C2908647359 @default.
• W4281645352 hasConcept C33191230 @default.
• W4281645352 hasConcept C35785553 @default.
• W4281645352 hasConcept C50522688 @default.
• W4281645352 hasConcept C70410870 @default.
• W4281645352 hasConcept C71924100 @default.
• W4281645352 hasConcept C99454951 @default.
• W4281645352 hasConceptScore W4281645352C124306116 @default.
• W4281645352 hasConceptScore W4281645352C126322002 @default.
• W4281645352 hasConceptScore W4281645352C133925201 @default.
• W4281645352 hasConceptScore W4281645352C160735492 @default.
• W4281645352 hasConceptScore W4281645352C162324750 @default.
• W4281645352 hasConceptScore W4281645352C171606756 @default.
• W4281645352 hasConceptScore W4281645352C1862650 @default.
• W4281645352 hasConceptScore W4281645352C187212893 @default.
• W4281645352 hasConceptScore W4281645352C194828623 @default.
• W4281645352 hasConceptScore W4281645352C2908647359 @default.
• W4281645352 hasConceptScore W4281645352C33191230 @default.
• W4281645352 hasConceptScore W4281645352C35785553 @default.
• W4281645352 hasConceptScore W4281645352C50522688 @default.
• W4281645352 hasConceptScore W4281645352C70410870 @default.
• W4281645352 hasConceptScore W4281645352C71924100 @default.
• W4281645352 hasConceptScore W4281645352C99454951 @default.
• W4281645352 hasFunder F4320314126 @default.
• W4281645352 hasIssue "1" @default.
• W4281645352 hasLocation W42816453521 @default.
• W4281645352 hasLocation W42816453522 @default.
• W4281645352 hasOpenAccess W4281645352 @default.

• next